THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. reported its third-quarter and nine-month financial results for 2026. The company saw a year-over-year increase in both quarterly and year-to-date revenues and earnings per share. Total assets and long-term obligations also saw increases, with significant investment in acquisitions during the nine-month period.

Thermo Fisher Scientific Inc. reported strong financial results for the first half of 2026, with total revenues increasing by 8.4% to $23.0 billion and diluted EPS rising to $9.10. Net income attributable to the company grew by 8.4% to $3.39 billion. The company also significantly increased its share buybacks to $4.0 billion and invested $8.87 billion in acquisitions during the period, while generating $3.32 billion in operating cash flow.

Thermo Fisher Scientific reported strong second-quarter 2026 financial results, with revenue growing 10% to $11.99 billion and adjusted EPS increasing 13% to $6.03. The company highlighted strengthening customer activity across its end markets and successful execution of its growth strategy, including new product launches and strategic collaborations. Capital deployment included the divestiture of its microbiology business and $1.0 billion in stock repurchases.

Thermo Fisher Scientific Inc. reported strong financial results for the first quarter of 2026, with total revenues increasing 6.2% to $11.01 billion and diluted EPS growing 11.3% to $4.43. The company also saw a significant 9.6% rise in net income attributable to shareholders, reaching $1.65 billion. Operating cash flow improved substantially, and the quarter included $8.87 billion in acquisitions and $3.00 billion in share repurchases, indicating active capital deployment.

Thermo Fisher Scientific Inc. announced its financial results for the fiscal quarter ended March 28, 2026. The announcement was made on April 23, 2026, and the full details are available in a press release furnished as Exhibit 99.1 to the Form 8-K filing. This filing serves to formally disclose the release of the company's latest quarterly financial performance.

Thermo Fisher Scientific has announced a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash, plus potential deferred and contingent consideration. The acquisition is expected to close by mid-2026 and will expand Thermo Fisher's capabilities in the clinical trial technology and services space.

Thermo Fisher Scientific's finance subsidiary issued €1 billion in Floating Rate Senior Notes due 2027 and €1.1 billion in 3.628% Fixed Rate Senior Notes due 2035 in a public offering. The notes are fully and unconditionally guaranteed by Thermo Fisher Scientific, indicating a move to raise capital, likely for general corporate purposes or strategic initiatives.

Thermo Fisher Scientific's finance subsidiary issued €1 billion in Floating Rate Senior Notes due 2027 and €1.1 billion in 3.628% Senior Notes due 2035 in a public offering. The notes are fully and unconditionally guaranteed by Thermo Fisher Scientific Inc., indicating a move to raise capital, likely for general corporate purposes or strategic initiatives.

Thermo Fisher Scientific announced that Executive Vice President and Chief Operating Officer Michel Lagarde and Executive Vice President Frederick M. Lowery will depart the company in March and February 2026, respectively. Gianluca Pettiti, currently an Executive Vice President, will be promoted to President and Chief Operating Officer, effective March 1, 2026. These changes represent a significant shift in the company's leadership structure.

Thermo Fisher Scientific reported its Q4 and full-year 2025 financial results. Q4 revenue increased by 7% to $12.21 billion, and adjusted EPS grew by 8% to $6.57, indicating strong financial performance. The company also highlighted strategic collaborations, acquisitions, and product launches, demonstrating continued growth and innovation.